Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Dignitana AB Publishes Q4 2022 Interim Report

Focused growth of 25 percent: Scaling up with a commitment to patients Financial highlights Q4 2022 · Net sales amounted to 20.2 MSEK (16.2), an increase of 25 percent over the same period in 2021. · Operating result amounted to -10.9 MSEK (-11.4). · Net result after financial items amounted to -12.9 MSEK (-11.8). · Earnings per share were -0.17 SEK (-0.10). · Cash Balance amounted to 8.9 MSEK (14.5). · Average Daily Treatment Revenue (ADTR)* was 229 TSEK (155), an increase of 48 percent over the same period in 2021. Financial highlights January - December 2022

Fellow Bank Plc’s Financial Statements Bulletin 2022

FELLOW BANK PLC STOCK EXCHANGE RELEASE 16.2.2023 AT 9:00 AM EETGrowth continued and profitability improved in the second half · Launching banking operations and merger with Evli Bank were operationally excellent. Digital banking services have received a positive response from customers. · Loan portfolio increased during the period to EUR 163.8 million (18.1) exceeding the targeted level of EUR 150 million · Profit before taxes EUR -9.7 million (-1.5) was negative as expected due to the non-recurring costs related to the investments required by the credit institution's operations

Metacon publishes Year-end report for 2022

Metacon contributes to the green hydrogen market's transformation and saw rapid sales growth in 2022. The board and CEO of Metacon AB (publ) hereby issue the Year-end report for (January 1 – December 31) 2022. Fourth quarter in summary (Group) · Revenues amounted to 12 250 (11 741) kSEK · Earnings before depreciation and amortization (EBITDA) amounted to -12 173 (-6 204) kSEK · Operating income (EBIT) amounted to 5 575 (-16 959) kSEK. Earnings were positively impacted by a one-off effect of 27 700 kSEK due to an adjusted accounting policy* regarding the recognition of goodwill

Valio and VTT researching the use of plasma technology to convert barn air methane into carbon dioxide

Valio and VTT, Technical Research Centre of Finland Ltd, are participating in an international research project exploring the use of plasma technology to capture the methane in barn air and break it down into carbon dioxide. In Finnish conditions, the methane emissions generated in conjunction with milk production account for about 50 percent of milk’s carbon footprint. The goal of the research project is to develop equipment that can convert the greenhouse gas methane that is captured from barn air into less harmful carbon dioxide.In milk production, methane is generated in the cow’s rumen

Invitation to presentation of Ranplan’s Annual Statement 2022

Stockholm, Sweden, 16 February 2023 – Ranplan Group AB is pleased to invite media, investors, shareholders and financial analysts to a video conference meeting from its office in the city of Stockholm. On this occasion, CEO Per Lindberg and CSO Jon Ullmark will present the Annual Statement (Year-End Report) 2022. Those who want to participate on-line at this event should notify the company of their interest before 6pm CET on 23 Feb 2023 by sending an e-mail to joyce.wu@ranplanwireless.com (joyce.wu@ranplanwireless.com?subject=Invitation%20request%20for%20Ranplan's%20Annual%20Statement%

Ruukki modernizes Vimpeli plant’s bending machine: even better profile products for customers

Ruukki ConstructionPress release16.2.2023Ruukki Construction, part of SSAB group, completed the modernization of the bending machine at the Vimpeli plant in Finland in January 2023. The modernization is part of the Ruukki-wide investment program and the Vimpeli Flow investment project that started in December 2021. The project aims to improve employee safety and efficiency, reduce plant emissions by improving energy efficiency, and to support Ruukki’s strategic target to grow sustainably together with customers by ensuring the high quality of customer deliveries.   At the turn of

AQ Group AB (publ): Year-end report 2022

Fourth quarter, October-December 2022 in brief · Record turnover and record profit · Net sales increased by 31.8% to SEK 1,974 million (1,498) · Operating profit (EBIT) increased by 30.5%to SEK 148 million (113) · Profit after financial items (EBT) increased by 23.7%to SEK 137 million (110) · Profit margin before tax (EBT %) was 6.9% (7.4) · Cash flow from operating activities amounted to SEK 140 million (-105) · Earnings per share after dilution increased by 52.6%to SEK 7.27 (4.76) Full year 2022 in brief · Net sales increased by 28.9%to SEK 7,053 million (5,

Year-end report January – December 2022

Highlights“The fourth quarter of 2022 served as a bookmark to a truly remarkable year for Storytel. We completed the transformation of our strategy, a significant restructuring of our activities and organization, and strengthened our balance sheet, and implemented our focus on profitable growth. We achieved another strong EBITDA margin in Q4 and positive EBITDA for the entire year. And, we ended 2022 as a more focused company with clear priorities on profitability and growth in our core markets, and a strong strategic commitment to expanding our content leadership and marketing

Peab builds new swimming pool facility in Nacka

Peab has been commissioned to build a new swimming pool facility in Saltsjöbaden, south of Stockholm. The customer is Nacka Municipality and the contract is worth SEK 265 million.The project entails building a new swimming pool facility, Näckenbadet, doing the associated groundwork and tearing down the existing swimming pool facility. It will be built on two floors and contain a 25 meter pool with six swimming lanes, a training pool with a height adjustable bottom and personnel space. “We’re proud to be part of building this new swimming pool facility. It will be a fine meeting place for

Alligo Year-end Report 1 Jan–31 Dec 2022 - Profitable growth on all markets

Fourth quarter highlights · Revenue increased by 11.8 per cent to MSEK 2,723 (2,436). · EBITA increased by 19 per cent to MSEK 298 (250), corresponding to an EBITA margin of 10.9 per cent (10.3). · Operating profit amounted to MSEK 268 (194) and the operating margin was 9.8 per cent (8.0). · Operating profit was charged with items affecting comparability of MSEK -15 (-40), which comprise costs for organisational changes of MSEK -9 and rental costs for the coordination of logistics of MSEK -6. · Profit from continuing operations amounted to MSEK 194 (139), profit from

Polygiene Group AB (publ.) Interim Report October 1 – December 31, 2022

Sales stabilize despite a challenging world situationDespite the world situation, we are able to keep our positions and deliver turnover at the same level as previous quarter. This can be considered satisfactory since historically, revenues in the last quarter of every year tend to be lower than in other quarters.  To finance new key recruitments and stand stronger in 2023, a restructuring program was carried out in December. This resulted in company layoffs of four staff members. Two others also left the company in January, bringing the number of staff members lost due to employee

Cereno Scientific selects prevention of thrombosis as target indication for its candidate drug CS014

Cereno Scientific (XSAT: CRNO B) today announced that the company’s preclinical drug candidate CS014 will continue toward clinical development for thrombosis prevention. CS014, a novel HDAC inhibitor with epigenetic effects, has, in preclinical studies, demonstrated anti-thrombotic properties supporting the selection of target indications with the aim of preventing thrombosis. The drug candidate is currently in the final stages of its preclinical development program, and a Phase I study is expected to start in 2024.“CS014 has demonstrated promising anti-thrombotic properties in its ongoing

Prostatype Genomics presents Quarterly- & Year End Report

Prostatype Genomics AB has today published its quarterly report for the fourth quarter comprising the period from 1 October 2022 to 31 December 2022, and the year end report for the financial year 2022. The report is available on the company website.Quarter 4 (1 October – 31 December 2022) summarized · Net sales amounted to 304 (0) TSEK. · EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -7 673 (-5 712) TSEK. · Cash flow from current operations in the quarter amounted -7 850 (-5 381) TSEK. · Total cash flow for the period amounted to – 7 950

Nilar International AB Year-end Report 2022

Nilar continues to execute on revised strategyOctober – December 2022 in summary · Net sales, MSEK 1.5 (-0.1). · Delivered batteries 20 (228). · Gross profit MSEK -43.2 (-237.7). · EBITDA1 MSEK -57.0 (-110.6). · Operating profit (EBIT) MSEK -73.3 (-269.5). · Profit for the period MSEK -81.6 (-251.5). · Earnings per share before/after dilution SEK -0.26 (-1.75). January - December 2022 in summary · Net sales MSEK 0.3 (17.8). · Delivered batteries 592 (3 187). · Gross profit MSEK -150.3 (-479.5). · EBITDA MSEK -185.8 (-382.1). · Operating profit (

Navamedic ASA: Q4 2022 financial results

Oslo, 16 February 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces its results for the fourth quarter of 2022. In the period, Navamedic delivered another quarter with solid growth across its portfolio, resulting in a 29 per cent increase in revenues to NOK 116.0 million compared to the same quarter in 2021. For the full year of 2022, revenues amounted to NOK 382.1 million, up 37 per cent compared to 2021.“The fourth quarter completed an eventful year for Navamedic. Product launches,

Lytix Biopharma presents fourth quarter and second half 2022 results

Oslo, 16 February 2023. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, today releases its fourth quarter and second half 2022 results – Steady progress towards improving cancer treatment outcomes.“Our molecules have a unique dual mode of action and can kill cancer cells in a way that activates a broad T-cell response that has the potential to target all cancer cells within heterogeneous tumors and thereby increase the number of patients responding to immunotherapy. We have seen very promising effects in cancer patients and are now eagerly

IRRAS AB publishes Year End Report for the period January to December 2022

Commercial partnership underway to wrap up meaningful year of growth “Q4 2022 marked the conclusion of a transformational year for IRRAS, and, as we begin the new year, we have created new opportunities that will accelerate our growth toward achieving leadership in the world of neurocritical care.” “The 4th quarter also marked the start of an extremely exciting next phase for the launch of IRRAflow, our lead product, with the announcement of our commercial partnership with Medtronic, the world’s largest medical device company.” Will Martin, CEO of IRRASFourth quarter, October –

Year-end report 1 January – 31 December 2022

Fourth QUARTER (1 October–31 December 2022) · Net sales for the quarter amounted to MSEK 106 (79). · Operating profit before depreciation and amortisation (EBITDA) totalled MSEK 52 (46) before items affecting comparability and MSEK 52 (32) after items affecting comparability. · Operating profit (EBIT) amounted to MSEK 37 (31) before items affecting comparability and MSEK 37 (17) after items affecting comparability. · Profit after tax totalled MSEK 36 (13), corresponding to SEK 0.80 (0.33) per share before and after dilution. · Operating cash flow was MSEK -3 (23) and cash

Metsä Group has revised its strategic sustainability targets

Metsä Group press release 16 February 2023Metsä Group has revised its 2030 sustainability targets as part of the Group’s strategy work. The revision of the targets is a step towards a fossil free and waste-free future that bolsters nature. The company’s climate actions are based on both global climate change mitigation and adapting to it in Finland’s changing climate. Focusing on the most essential sustainability issues, the targets cover all of Metsä Group’s operations and will also affect supply chains. In particular, Metsä Group is working to increase measures improving forests’

Notice to the Annual General Meeting of Terveystalo Plc

Terveystalo Plc, Stock Exchange Release, 16 February 2023 at 9:00 EET   Notice is given to the shareholders of Terveystalo Plc (the "Company") to participate in the Annual General Meeting to be held on Thursday, 23 March 2023 at 3.00 p.m. (EET) in the event center Pikku Finlandia at Karamzininranta 4, 00100 Helsinki, Finland. The reception of participants and the distribution of voting tickets will commence at the meeting venue at 2:00 p.m. (EET).   Shareholders and their proxy representatives may also exercise their voting rights by voting in advance. Instructions for advance

YIT’s Annual Review for 2022 published

YIT Corporation Stock Exchange Release 16 February 2023 at 9:00 a.m.YIT’s Annual Review for 2022 published YIT’s Annual Review for 2022 has been published today on the company’s website. The Annual Review consists of the highlights of 2022, report of the Board of Directors, consolidated financial statements, parent company’s financial statements, corporate governance statement and remuneration report. The report of the Board of Directors contains YIT’s statement of non-financial information. In addition, YIT publishes the Annual Review in accordance with European Single Electronic

Year-end report January-December 2022

Stable finish to the year   Quarter 4, 2022 · Incoming orders amounted to SEK 1,396m (1,352), equivalent to a currency neutral decrease of 6.7 percent compared with the same period last year. · Net sales amounted to SEK 1,515m (1,152), equivalent to currency neutral growth of 20.4 percent compared with the same period last year. · Adjusted EBITA was SEK 161.1m (143.9), giving an adjusted EBITA margin of 10.6 percent (12.5). · Net profit was SEK 90.9m (84.4). · Earnings per share were SEK 2.59 (2.41). · Cash flow from operating activities amounted to SEK 87.8m (159.

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseFebruary 16, 2023, at 9.00 am EETRepurchase of Outokumpu’s own shares On February 15, 2023, Outokumpu has completed repurchases its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |23,753 |5.3536

The Ship joins Dataloy Partner Program

The Partnership Between Dataloy And The Ship Enables Customers To Streamline And Digitize Port Data CollectionNorway, 16 February 2023 The Ship AS, a leading provider of data collection solutions, and Dataloy, a leading voyage management system, are proud to announce their partnership. Integrating The Ship’s expertise in data collection and Dataloy’s experience in voyage management will provide customers with a comprehensive and streamlined solution for optimizing the collection of voyage, cargo, and laycan data, resulting in a streamlined and efficient port call procedure. · Key

There are no items matching the current filter
There are no more items matching the current filter
Back to top